KRIMISH BHAGAT: Open Payments
NPI 1760001770 · SALEM, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,091 in 98 payments from 16 companies in 2025. Trend: 2023 $520 · 2024 $1,150 · 2025 $2,091
Food & beverage: $2,091
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $561 |
| AstraZeneca Pharmaceuticals LP | 17 | $388 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $237 |
| Lilly USA, LLC | 9 | $190 |
| Lundbeck LLC | 5 | $104 |
| Novo Nordisk Inc | 5 | $102 |
| PFIZER INC. | 4 | $99 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Amgen Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
Products named: CAPLYTA, QULIPTA, UBRELVY, BREZTRI, AIRSUPRA, VRAYLAR, REXULTI, NURTEC ODT.
Industry payments across NH — which companies pay providers there.
